Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation

Inclusion Criteria: * Patients aged \>= 18 and \<= 80 years; * Successfully established ECMO (VA/VV) treatment by percutaneous puncture due to cardiogenic shock or respiratory failure; * Anticoagulation required during ECMO treatment; Before the establishment of ECMO, the APTT test value was within the normal range, and the platelets were not less than 80G/L; * Within 48 hours of ECMO establishment, APTT test results were between 1 and 1.75 times the upper limit of normal, PLT\>80 G/L, and no serious bleeding and thrombosis; * Sign the informed consent. Exclusion Criteria: * Pregnant; * Bleeding risk or active bleeding; * Pre-existing diseases requiring long-term anticoagulation before ECMO: pulmonary embolism, deep vein thrombosis, intraventricular thrombosis, atrial fibrillation, etc.; * Long-term use of anticoagulants before ECMO; * Antiplatelet drugs were used before ECMO; * Allergy to heparin, nafamostat mesylate; * Repeated puncture at the same site for more than 3 times; * Expected ECMO treatment time \< 3 days; * Patients with an expected survival period of less than 48 hours; * Patients undergoing extracorporeal cardiopulmonary resuscitation; * Burn patients; Blood purification treatment using polyacrylonitrile membrane filter; * Heterozygous ECMO mode or ECMO therapy solely for CO2 removal; * Other reasons that the investigator considers inappropriate for inclusion;